middl
east
respiratori
syndrom
mer
cov
emerg
pathogen
caus
sever
pneumonia
human
arabian
peninsula
travel
region
assiri
et
al
zaki
et
al
zumla
et
al
humantohuman
spread
document
assiri
et
al
infect
immunocompet
patient
gener
present
mild
symptom
elderli
patient
preexist
ill
diabet
renal
failur
like
develop
sever
diseas
assiri
et
al
septemb
case
death
mortal
report
world
health
organ
although
actual
number
infect
could
much
larger
sinc
mild
asymptomat
undiagnos
case
like
common
drosten
et
al
yet
neither
licens
vaccin
prophylact
therapeut
treatment
effect
merscov
given
abil
coronavirus
rapidli
adapt
new
host
major
public
health
concern
merscov
adapt
replic
human
trigger
global
sever
acut
respiratori
syndrom
sar
like
pandem
peiri
et
al
zaki
et
al
promis
treatment
passiv
administr
antimerscov
neutral
antibodi
sever
research
group
develop
produc
antim
patientderiv
human
monoclon
neutral
antibodi
vitro
abl
protect
merscov
infect
mice
corti
et
al
li
et
al
zhao
et
al
howev
sinc
antibodi
react
singl
epitop
merscov
spike
protein
sinc
coronavirus
prone
mutat
approach
rais
concern
possibl
antibodi
escap
corti
et
al
sabir
et
al
recent
show
sera
middl
east
dromedari
camel
contain
high
level
antimerscov
neutral
antibodi
passiv
immunotherapi
sera
anim
significantli
reduc
viru
load
acceler
viru
clearanc
lung
merscov
infect
mice
provid
proof
concept
immun
anim
sera
potenti
use
treatment
patient
mer
hayden
et
al
passiv
immunotherapi
anim
sera
antibodi
success
use
prevent
rabi
neutral
snake
venom
et
al
gutierrez
et
al
convalesc
plasma
use
treat
patient
sar
found
safe
demonstr
efficaci
studi
small
number
patient
mairjenkin
et
al
howev
neutral
antibodi
titer
mer
patient
gener
low
limit
number
mer
survivor
make
approach
impract
drosten
et
al
show
immun
healthi
hors
merscov
viruslik
particl
vlp
express
merscov
e
protein
induc
strong
polyclon
neutral
antibodi
merscov
sinc
administr
whole
antibodi
induc
allerg
respons
human
test
f
ab
fragment
prepar
digest
antibodi
pepsin
prophylact
therapeut
treatment
merscov
infect
mice
either
igg
f
ab
significantli
decreas
viru
load
lung
merscov
vlp
produc
purifi
previous
describ
brief
armi
worm
cell
infect
singl
recombin
baculovirus
coexpress
merscov
structur
protein
gene
e
multipl
infect
moi
cultur
supernat
harvest
h
postinfect
centrifug
g
min
remov
cell
debri
follow
centrifug
clarifi
supernat
g
h
c
result
vlp
pellet
resuspend
pb
load
onto
discontinu
sucros
gradient
addit
centrifug
g
h
c
band
sucros
contain
merscov
vlp
collect
four
healthi
hors
receiv
multipoint
intramuscular
inject
mg
merscov
vlp
ml
pb
week
respect
freund
complet
adjuv
sigma
includ
first
dose
incomplet
adjuv
remain
one
sera
collect
jugular
vein
week
inject
store
c
analysi
merscov
specif
antibodi
sera
measur
indirect
enzymelink
immunosorb
assay
elisa
use
purifi
merscov
receptorbind
domain
rbd
protein
ie
protein
residu
clone
express
vector
purifi
ninta
affin
chromatograph
column
briefli
microtitr
plate
corn
costar
usa
precoat
ml
purifi
rbd
antigen
dilut
moll
carbon
sodium
buffer
ph
final
concentr
mg
ml
incub
c
overnight
block
skim
milk
h
c
ml
twofold
serial
dilut
serum
sampl
ad
well
incub
c
h
plate
wash
three
time
pb
contain
pbst
addit
ml
hrplabel
rabbit
antibodi
hors
igg
bioss
china
incub
c
h
wash
pbst
ml
tmb
sigma
usa
substrat
ad
well
incub
min
reaction
stop
ml
h
optic
densiti
nm
measur
elisa
plate
reader
biorad
usa
hors
antiserum
dilut
vol
normal
salin
nacl
half
volum
satur
ammonium
sulfat
ad
mix
gentli
room
temperatur
min
centrifug
g
min
result
sediment
redissolv
salin
mix
onethird
volum
satur
ammonium
sulfat
incub
ambient
temperatur
min
centrifug
g
min
second
sediment
dissolv
normal
salin
dialyz
normal
salin
remov
remain
ammonium
salt
immunoaffin
resin
prepar
coupl
mg
rbd
protein
sodium
periodateactiv
sepharos
g
incub
ml
sodium
borohydrid
min
reaction
tri
ph
min
purifi
igg
sampl
dilut
pb
incub
rbd
resin
overnight
c
constant
rotat
flowthrough
antirbd
deplet
collect
flowthrough
test
rbd
protein
elisa
ensur
rbdspecif
igg
bound
rbd
sepharos
wash
pb
bound
antibodi
antirbd
elut
glycinehcl
buffer
ph
eluat
neutral
tri
buffer
ph
dialyz
pb
sampl
adjust
protein
concentr
steril
passag
microspin
filter
mm
pore
size
millipor
neutral
activ
igg
rbdspecif
igg
flowthrough
test
ph
hors
antiserum
adjust
moll
hcl
follow
incub
pepsin
iuml
c
h
reaction
stop
adjust
ph
moll
naoh
solut
appli
proteina
prote
column
sequenti
remov
whole
immunoglobulin
puriti
result
f
ab
protein
assess
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
follow
coomassi
blue
stain
target
fraction
gel
analyz
thin
layer
chromatographi
scanner
transmiss
zigzag
scan
dual
wavelength
swing
mm
delta
mm
shimadzu
specif
pathogenfre
week
old
balbc
mice
purchas
charl
river
laboratori
intern
maintain
anim
care
facil
univers
iowa
briefli
mice
hous
thoren
individu
ventil
cage
cage
bed
autoclav
irradi
diet
fed
filter
water
mm
filter
provid
edstrom
automat
water
system
hepafilt
cage
chang
station
use
person
enter
anim
room
worn
autoclav
gown
glove
hair
bonnet
face
mask
shoe
cover
serum
sampl
purifi
igg
f
ab
serial
dilut
dmem
mix
equal
volum
merscov
contain
pfu
follow
incub
c
h
aliquot
ad
cultur
vero
cell
well
plate
incub
c
co
h
gentl
rock
everi
min
plate
overlaid
calf
serum
incub
day
agaros
plug
remov
use
small
spatula
remain
plaqu
visual
stain
crystal
violet
sixweekold
femal
balbc
mice
lightli
anesthet
isofluran
transduc
intranas
pfu
ml
dmem
describ
elsewher
zhao
et
al
five
day
post
transduct
mice
infect
intranas
merscov
pfu
total
volum
ml
dmem
mice
monitor
daili
morbid
weight
loss
mortal
work
merscov
conduct
univers
iowa
biosafeti
level
laboratori
separ
group
inject
ml
hors
antiserum
mg
igg
f
ab
intraperiton
ip
day
intranas
infect
pfu
merscov
control
mice
given
equal
volum
normal
hors
serum
sigma
obtain
viru
titer
lung
harvest
subgroup
anim
indic
time
point
see
result
homogen
ml
phosphat
buffer
salin
pb
use
manual
homogen
lung
homogen
aliquot
micro
tube
kept
c
viru
titer
vero
cell
cell
fix
formaldehyd
stain
crystal
violet
three
day
postinfect
pi
viral
titer
express
pfug
tissu
merscov
zhao
et
al
due
biosafeti
risk
merscov
must
handl
laboratori
wherea
vlp
rapidli
gener
condit
immunogen
induc
high
antibodi
titer
addit
hors
provid
littl
risk
human
produc
high
antibodi
yield
make
anim
effect
sourc
product
hyperimmun
sera
zheng
et
al
rbdspecif
igg
titer
sera
five
immun
fig
assess
elisa
rbd
contain
major
neutral
epitop
protein
shown
observ
absorpt
sar
patient
convalesc
sera
sarscov
rbd
remov
major
neutral
antibodi
et
al
independ
research
group
also
shown
directli
merscov
rbd
sequenc
contain
major
antigen
determin
induc
neutral
antibodi
neutral
epitop
within
merscov
also
local
primarili
rbd
region
du
et
al
mou
et
al
demonstr
antirbd
antibodi
function
major
compon
neutral
antibodi
found
rbdspecif
igg
neutral
merscov
infect
half
maxim
inhibitori
concentr
mgml
mgml
flowthrough
fig
suggest
rbd
protein
act
import
neutral
determin
merscov
result
demonstr
equin
antibodi
polyclon
recogn
antigen
determin
merscov
protein
singl
mab
could
potenti
prevent
antibodi
escap
integr
igg
f
ab
fragment
evalu
use
sdspage
gel
fig
puriti
f
ab
fragment
proteinag
chromatographi
gel
electrophoresi
fig
passiv
transfer
blood
product
human
pose
safeti
concern
possibl
contamin
agent
bloodborn
diseas
eg
hiv
hepat
heterolog
antibodi
carri
potenti
risk
allerg
reaction
gener
f
ab
fragment
result
antibodi
less
immunoreact
safer
use
human
success
gener
equin
antibodi
merscov
vlp
protect
effect
authent
mer
fig
robust
merscov
rbdspecif
antibodi
immun
hors
sera
hors
n
inject
intramuscularli
merscov
vlp
boost
everi
two
week
addit
time
sera
collect
week
immun
rbdspecif
antibodi
immun
hors
sera
detect
use
elisa
cov
infect
remain
untest
use
plaqu
reduct
neutral
assay
confirm
immun
sera
significantli
neutral
merscov
infect
vitro
half
effect
maxim
dilut
fig
b
found
equin
igg
f
ab
also
neutral
merscov
infect
half
effect
maxim
concentr
ec
mgml
mgml
igg
f
ab
respect
fig
collect
result
show
equin
antibodi
product
exhibit
highli
potent
neutral
activ
merscov
next
ask
adopt
transfer
equin
antibodi
could
protect
mice
merscov
infect
prophylact
therapeut
use
mous
model
previous
gener
zhao
et
al
inject
anim
immun
serum
fig
b
purifi
igg
fig
f
ab
fig
f
ip
day
fig
c
e
fig
f
merscov
challeng
prophylact
therapeut
set
passiv
transfer
equin
immun
antibodi
result
log
reduct
viru
titer
lung
merscov
infect
mice
acceler
viru
clearanc
serum
treat
group
fig
b
observ
differ
bodi
weight
loss
patholog
chang
exterior
surfac
lung
treat
untreat
mice
fig
neutral
activ
rbdspecif
antibodi
igg
vitro
neutral
test
total
igg
rbdspecif
igg
flowthrough
determin
seri
dilut
neutral
calcul
use
graphpad
prism
infeciton
sinc
model
mice
develop
mild
lung
diseas
rapid
viru
replic
inflammatori
cell
infiltr
infect
lung
major
paramet
measur
zhao
et
al
sinc
halflif
f
ab
vivo
rel
short
merscov
clear
within
day
model
zhao
et
al
inject
f
ab
antibodi
day
day
pi
note
purifi
igg
seem
lower
protect
potenc
immun
serum
vivo
fig
concentr
igg
serum
mgml
use
ml
immun
serum
equal
mg
igg
per
mous
much
higher
immun
igg
use
mgmice
reason
could
purifi
immun
igg
use
satur
ammonium
sulfat
precipit
method
need
perform
room
temperatur
specul
igg
degrad
misfold
unabl
bind
merscov
spike
protein
circumst
immun
sera
properli
store
c
contain
high
concentr
bsa
protein
made
antiserum
stabl
date
sever
antimerscov
antibodi
develop
differ
origin
antibodi
contain
advantag
disadvantag
monoclon
antibodi
mousederiv
monoclon
antibodi
need
human
human
use
li
et
al
human
neutral
antibodi
deriv
convalesc
mer
patient
produc
larg
amount
cho
cell
corti
et
al
howev
singl
clone
antibodi
rais
concern
viral
escap
mutant
appli
human
administr
transchromosom
bovin
human
immunoglobulin
luke
et
al
dromedari
immun
serum
result
rapidli
viral
clearanc
infect
mous
lung
disadvantag
antibodi
anim
readili
avail
compar
antibodi
describ
administr
equin
iggderiv
f
ab
fragment
prove
versatil
feasibl
method
lu
et
al
zhou
et
al
provid
use
platform
produc
therapeut
emerg
infecti
diseas
summari
immun
healthi
hors
merscov
vlp
success
develop
first
equin
iggderiv
f
ab
fragment
neutral
merscov
vitro
vivo
prophylact
therapeut
treatment
decreas
viru
load
acceler
viru
clearanc
lung
merscovinfect
mice
therefor
hors
immun
merscov
vlp
serv
use
initi
sourc
develop
protect
f
ab
fragment
purpos
prepared
serv
strateg
reserv
potenti
mer
epidem
emerg
pathogen
author
declar
compet
interest
